Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
A. Michael Lincoff, Kirstine Brown‐Frandsen, Helen M. Colhoun et al.
Research Article — Peer-Reviewed Source
Original research published by Lincoff et al. in New England Journal of Medicine. Redistributed under Open Access — see publisher for license terms. MedTech Research Group provides these references for informational purposes. We do not conduct original research. All studies are the work of their respective authors and institutions.
In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Full text is available at the publisher.
Read at Publisher| DOI | 10.1056/nejmoa2307563 |
| Journal | New England Journal of Medicine |
| Year | 2023 |
| Authors | A. Michael Lincoff, Kirstine Brown‐Frandsen, Helen M. Colhoun, John Deanfield, Scott S. Emerson, Sille Esbjerg, Søren Hardt‐Lindberg, G. Kees Hovingh, Steven E. Kahn, Robert F. Kushner, Ildiko Lingvay, Tuğçe Kalaycı Oral, Marie Mide Michelsen, Jorge Plutzky, Christoffer W. Tornøe, Donna H. Ryan |
| License | Open Access — see publisher for license terms |
| Citations | 2,321 |